Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Qiu Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5158-3838; OpenAlex author ID A5100722032. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
14
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 3 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 8

  1. Causal Relationships Between Gut Microbiota, Immune Cell and Pancreatic Cancer: A Two-Step, Two-Sample Mendelian Randomization Study. Last author DOI 10.14740/wjon1960↗
  2. Signalling in pancreatic cancer: from pathways to therapy. Last author DOI 10.1080/1061186x.2023.2274806↗
  3. Hic-5 in pancreatic stellate cells affects proliferation, apoptosis, migration, invasion of pancreatic cancer cells and postoperative survival time of pancreat… Co-author DOI 10.1016/j.biopha.2019.109355↗
  4. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial. Last author DOI 10.1080/14737167.2020.1677155↗
  5. Predictive value of CONUT score combined with serum CA199 levels in postoperative survival of patients with pancreatic ductal adenocarcinoma: a retrospective s… Co-author DOI 10.7717/peerj.8811↗
  6. Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial. Last author DOI 10.2147/cmar.s172704↗
  7. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials. Last author DOI 10.5301/tj.5000499↗
  8. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study. Last author DOI 10.1007/s12032-015-0580-4↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kexun Zhou · 3 shared papers, 2018–2023 · strength 0.38
  2. Ting Yu · 1 shared paper, 2024 · strength 0.26
  3. Si Ming Wang · 1 shared paper, 2024 · strength 0.26
  4. Ankang Wang · 2 shared papers, 2020 · strength 0.21
  5. Wenguang Fu · 2 shared papers, 2020 · strength 0.21
  6. Jiaxing Huang · 2 shared papers, 2018–2020 · strength 0.18
  7. Weiting Liao · 2 shared papers, 2018–2020 · strength 0.18
  8. Jing Zhou · 2 shared papers, 2015–2016 · strength 0.11
  9. Jian Zhang · 2 shared papers, 2015–2016 · strength 0.11
  10. Yu Jiang · 1 shared paper, 2020 · strength 0.11
  11. Zhiwei Huang · 1 shared paper, 2020 · strength 0.11
  12. Zhongqiu Yang · 1 shared paper, 2020 · strength 0.11
  13. Baolin Qian · 1 shared paper, 2020 · strength 0.11
  14. Hao Chen · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.